White Paper: Leveraging Technology Transfer to Improve Access to Medicines

With 450,000 new cases of multi-drug resistant tuberculosis (MDR-TB) each year resulting in 170,000 deaths, there is a clear global health imperative to find effective and sustainable solutions.

Technology transfer and public private partnerships are just two ways in which the private sector engages in supporting health and growth in developing countries.

With the European Institutions currently looking at the role of the private sector in contributing to growth and bridging the technology gap, Eli Lilly & Co. is sharing a case study on its 10-year effort to transfer its manufacturing technology, know-how and expertise for two medicines to address MDR-TB.

The objective was simple enough: create a sustainable, high quality global supply of two MDR-TB medicines by identifying qualified manufacturers in MDR-TB hot spot countries and donate the manufacturing technology, know-how and intellectual property. These partner companies are located in China, India, Russia and South Africa, where nearly 60 percent of the world’s MDR-TB cases are found.

A decade later, the project has demonstrated the huge potential of technology transfer in fighting MDR-TB as well as the challenges, while also offering important insights for governments, companies and others considering technology transfers to solve complex development problems.

Download the White Paper for details and see this infographic for a quick overview: http://www.lillyglobalhealth.com/en/media/pdfs/lilly-mdr-tb-technology-transfer.pdf.